FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Heide Ford

Research Profile

Chemicals & Drugs

Disorders

Living Beings

Anatomy

Physiology

Procedures

Neoplasm Transplantation

Co-author Network

Publications

TOP 3
Aaron N Patrick; Anna L Smith; Joshua H Cabrera; Xiaojiang S Chen; Heide L Ford; Rui Zhao
Structure-function analyses of the human SIX1-EYA2 complex reveal insights into metastasis and BOR syndrome.
L Y Dimberg; C K Anderson; Kian Behbakht; D Ross Camidge; Andrew Thorburn; Heide L Ford
On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics.
Aaron B Krueger; Xueni Li; Juan J Marugan; Noel Southall; Seameen J Dehdashti; Marc Ferrer; Heide L Ford; Wei Zheng; Rui Zhao
Identification of a selective small-molecule inhibitor series targeting the eyes absent 2 (Eya2) phosphatase activity.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Heide Ford (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Aaron N Patrick; Anna L Smith; Joshua H Cabrera; Xiaojiang S Chen; Heide L Ford; Rui Zhao
Structure-function analyses of the human SIX1-EYA2 complex reveal insights into metastasis and BOR syndrome.
Nature structural & molecular biology 2013;20(4):447-53.
2013: L Y Dimberg; C K Anderson; Kian Behbakht; D Ross Camidge; Andrew Thorburn; Heide L Ford
On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics.
Oncogene 2013;32(11):1341-50.
2013: Aaron B Krueger; Xueni Li; Juan J Marugan; Noel Southall; Seameen J Dehdashti; Marc Ferrer; Heide L Ford; Wei Zheng; Rui Zhao
Identification of a selective small-molecule inhibitor series targeting the eyes absent 2 (Eya2) phosphatase activity.
Journal of biomolecular screening 2013;18(1):85-96.
2012: A L Smith; A-C Tan; R L Vartuli; D J Drasin; R Iwanaga; D S Micalizzi; Heide L Ford
The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer.
Oncogene 2012;31(50):5162-71.
2012: Anna L Smith; Tyler P Robin; Heide L Ford
Molecular pathways: targeting the TGF-β pathway for cancer therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(17):4514-21.
2012: Tyler P Robin; Anna Smith; Paul Jedlicka; Erin McKinsey; Lisa Reaves; Heide L Ford
EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.
Molecular cancer research : MCR 2012;10(8):1098-108.
2012: Chu-An Wang; Matias Casás-Selves; Erin Deitsch; Joshua Chuck Harrell; Paul Jedlicka; Kimberly C Lemmer; Douglas S Micalizzi; Aaron N Patrick; Heide L Ford
SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer.
The Journal of clinical investigation 2012;122(5):1895-906.
2012: Lubna Qamar; Monique A Spillman; Andrew Thorburn; Erin Deitsch; Heide L Ford; Ritsuko Iwanaga; Aaron N Patrick; Miriam D Post; Kian Behbakht
Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancer.
Gynecologic oncology 2012;125(2):451-7.
2012: S M Farabaugh; Paul Jedlicka; D S Micalizzi; R Zhao; Heide L Ford
Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-β signaling, epithelial-mesenchymal transition, and cancer stem cell properties.
Oncogene 2012;31(5):552-62.
2011: Christina Menke; Lianghua Bin; Jacqueline Thorburn; Kian Behbakht; Heide L Ford; Andrew Thorburn
Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents.
Cancer research 2011;71(5):1883-92.
2011: David J Drasin; Tyler P Robin; Heide L Ford
Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity.
Breast cancer research : BCR 2011;13(6):226.
2011: Christina Menke; Tatiana Goncharov; Lubna Qamar; Christopher Korch; Heide L Ford; Kian Behbakht; Andrew Thorburn
TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitro.
PloS one 2011;6(1):e14527.
2010: Douglas S Micalizzi; Chu-An Wang; Susan M Farabaugh; William P Schiemann; Heide L Ford
Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth.
Cancer research 2010;70(24):10371-80.
2010: Heide L Ford; E W Thompson
Mammary gland studies as important contributors to the cause of epithelial mesenchymal plasticity in malignancy.
Journal of mammary gland biology and neoplasia 2010;15(2):113-5.
2010: Douglas S Micalizzi; Susan M Farabaugh; Heide L Ford
Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression.
Journal of mammary gland biology and neoplasia 2010;15(2):117-34.
2010: Ricardo D Coletta; Erica L McCoy; Valerie Burns; Kiyoshi Kawakami; James L McManaman; John J Wysolmerski; Heide L Ford
Characterization of the Six1 homeobox gene in normal mammary gland morphogenesis.
BMC developmental biology 2010;10():4.
2009: Douglas S Micalizzi; Heide L Ford
Epithelial-mesenchymal transition in development and cancer.
Future oncology (London, England) 2009;5(8):1129-43.
2009: Douglas S Micalizzi; Kimberly L Christensen; Paul Jedlicka; Ricardo D Coletta; Anna E Barón; J Chuck Harrell; Kathryn B Horwitz; Dean Billheimer; Karen A Heichman; Alana L Welm; William P Schiemann; Heide L Ford
The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling.
The Journal of clinical investigation 2009;119(9):2678-90.
2009: Erica L McCoy; Ritsuko Iwanaga; Paul Jedlicka; Nee-Shamo Abbey; Lewis A Chodosh; Karen A Heichman; Alana L Welm; Heide L Ford
Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition.
The Journal of clinical investigation 2009;119(9):2663-77.
2009: E L McCoy; K Kawakami; Heide L Ford; R D Coletta
Expression of Six1 homeobox gene during development of the mouse submandibular salivary gland.
Oral diseases 2009;15(6):407-13.
2009: Aaron N Patrick; Barbara J Schiemann; Kui Yang; Rui Zhao; Heide L Ford
Biochemical and functional characterization of six SIX1 Branchio-oto-renal syndrome mutations.
The Journal of biological chemistry 2009;284(31):20781-90.
2008: Ricardo D Coletta; Kimberly L Christensen; Douglas S Micalizzi; Paul Jedlicka; Marileila Varella-Garcia; Heide L Ford
Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation.
Cancer research 2008;68(7):2204-13.
2008: Andrew Thorburn; Kian Behbakht; Heide L Ford
TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2008;11(1-2):17-24.
2008: Kimberly L Christensen; Aaron N Patrick; Erica L McCoy; Heide L Ford
The six family of homeobox genes in development and cancer.
Advances in cancer research 2008;101():93-126.
2007: K L Christensen; J D G Brennan; C S Aldridge; Heide L Ford
Cell cycle regulation of the human Six1 homeoprotein is mediated by APC(Cdh1).
Oncogene 2007;26(23):3406-14.
2007: Kian Behbakht; Lubna Qamar; Carrie S Aldridge; Ricardo D Coletta; Susan A Davidson; Andrew Thorburn; Heide L Ford
Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival.
Cancer research 2007;67(7):3036-42.
2005: Marcia M Miller; Carren Wang; Emilio Parisini; Ricardo D Coletta; Ronald M Goto; Stella Y Lee; Duarte C Barral; Maria Townes; Carme Roura-Mir; Heide L Ford; Michael B Brenner; Christopher Dascher
Characterization of two avian MHC-like genes reveals an ancient origin of the CD1 family.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(24):8674-9.
2005: Kelly J Reichenberger; Ricardo D Coletta; Aline P Schulte; Marileila Varella-Garcia; Heide L Ford
Gene amplification is a mechanism of Six1 overexpression in breast cancer.
Cancer research 2005;65(7):2668-75.
2004: Ricardo D Coletta; Kimberly Christensen; Kelly J Reichenberger; Justin Lamb; Damian Micomonaco; Lili Huang; Douglas M Wolf; Carsten Müller-Tidow; Todd R Golub; Kiyoshi Kawakami; Heide L Ford
The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(17):6478-83.
2004: Ricardo D Coletta; Paul Jedlicka; Arthur Gutierrez-Hartmann; Heide L Ford
Transcriptional control of the cell cycle in mammary gland development and tumorigenesis.
Journal of mammary gland biology and neoplasia 2004;9(1):39-53.
2003: Justin Lamb; Sridhar Ramaswamy; Heide L Ford; Bernardo Contreras; Robert V Martinez; Frances S Kittrell; Cynthia A Zahnow; Nick Patterson; Todd R Golub; Mark E Ewen
A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer.
Cell 2003;114(3):323-34.
2003: Carren Wang; Thushara V Perera; Heide L Ford; Christopher Dascher
Characterization of a divergent non-classical MHC class I gene in sharks.
Immunogenetics 2003;55(1):57-61.
2001: Yan Geng; Qunyan Yu; W Whoriskey; Frederick A Dick; K Y Tsai; Heide L Ford; Debajit K Biswas; Arthur B Pardee; B Amati; T Jacks; Andrea Richardson; Nicholas J Dyson; Piotr Sicinski
Expression of cyclins E1 and E2 during mouse development and in neoplasia.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(23):13138-43.
2000: Heide L Ford; Esther Landesman-Bollag; Caroline S Dacwag; P Todd Stukenberg; Arthur B Pardee; David C Seldin
Cell cycle-regulated phosphorylation of the human SIX1 homeodomain protein.
The Journal of biological chemistry 2000;275(29):22245-54.
2000: R J Guan; Heide L Ford; Y Fu; Y Li; Leslie M Shaw; Arthur B Pardee
Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer.
Cancer research 2000;60(3):749-55.
1999: Heide L Ford; Arthur B Pardee
Cancer and the cell cycle.
Journal of cellular biochemistry 1999;Suppl 32-33():166-72.
1998: Heide L Ford; E N Kabingu; E A Bump; G L Mutter; Arthur B Pardee
Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIX1: a possible mechanism of breast carcinogenesis.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(21):12608-13.
1998: Heide L Ford
Homeobox genes: a link between development, cell cycle, and cancer?
Cell biology international 1998;22(6):397-400.
1998: Heide L Ford; Arthur B Pardee
The S phase: beginning, middle, and end: a perspective.
Journal of cellular biochemistry. Supplement 1998;30-31():1-7.
1997: Heide L Ford; Debra Silver; B Kachar; James R Sellers; S B Zain
Effect of Mts1 on the structure and activity of nonmuscle myosin II.
Biochemistry 1997;36(51):16321-7.
1995: Heide L Ford; M M Salim; R Chakravarty; V Aluiddin; S B Zain
Expression of Mts1, a metastasis-associated gene, increases motility but not invasion of a nonmetastatic mouse mammary adenocarcinoma cell line.
Oncogene 1995;11(10):2067-75.
1995: Heide L Ford; S B Zain
Interaction of metastasis associated Mts1 protein with nonmuscle myosin.
Oncogene 1995;10(8):1597-605.
1993: Eugene Tulchinsky; D Kramerov; Heide L Ford; E Reshetnyak; Eugene Lukanidin; S Zain
Characterization of a positive regulatory element in the mts1 gene.
Oncogene 1993;8(1):79-86.
1992: Eugene Tulchinsky; Heide L Ford; D Kramerov; E Reshetnyak; Mariam Grigorian; S Zain; E Lukanidin
Transcriptional analysis of the mts1 gene with specific reference to 5' flanking sequences.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(19):9146-50.